|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Combination treatment resulted in a significant upregulation of MMP-1 in normal fibroblasts compared with SSc fibroblasts, while in SSc fibroblasts MMP-9 expression was upregulated in response to treatment with TGF-β1 only.
|
30536805 |
2019 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upon TNF-α stimulation, normal dermal fibroblasts secrete more MMP-1 than systemic sclerosis (SSc) fibroblasts.
|
28884475 |
2018 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SSc-ICs but not NHS-ICs increased ICAM-1 expression, stimulated IL-6, IL-8, MMP-2, MCP-1, TGF-β1 and Pro-CollagenIα1 secretion, upregulated et-1, ifn-α, ifn-β, tlr2, tlr3 and tlr4, and activated NFκB, p38MAPK and SAPK-JNK. tlr9 was significantly upregulated by ARA-ICs, mmp-1 was significantly induced by ACA-ICs whereas colIα1 was not modulated by any SSc-ICs.
|
30157947 |
2018 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these findings suggest that miR-202-3p may function as a novel pro-fibrotic miRNA in SSc by inhibition the expression of MMP1.
|
28068631 |
2017 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we analyzed MMP1 -1607 1G/2G (rs1799750), MMP3 -1171 5A/6A (rs3025058), and MMP9 -1562 C/T (rs3918242) polymorphisms in relation to susceptibility to SSc and its clinical features.
|
28002595 |
2016 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, the inhibitory and stimulatory effects of rapamycin on the mRNA levels of COL1A2 and MMP1 genes, respectively, were significantly greater in SSc dermal fibroblasts than in normal dermal fibroblasts.
|
24630239 |
2014 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-17A increased MCP-1, IL-8 and MMP-1 production in a dose-dependent manner while having no effect on type I collagen in HD and SSc fibroblasts both at protein and mRNA levels.
|
24289089 |
2013 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Matrix metalloproteinase-1 (MMP-1) and TIMP-1 expression and secretion were measured by qRT-PCR and ELISA in circulating monocytes from patients with SSc, patients with rheumatoid arthritis (RA) and healthy controls (HC) and in healthy monocytes cultured in the presence of SSc or HC serum samples.
|
23223421 |
2013 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Connective tissue growth factor (CCN2) gene expression was significantly reduced and matrix metalloproteinase 1 (MMP1) levels were enhanced after ciprofloxacin treatment to a similar extent in healthy and SSc fibroblasts.
|
23041765 |
2012 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies indicated SSc dermal fibroblasts overexpress HGF receptor c-met, which suggest specific and effective induction of MMP-1 in SSc fibroblasts caused by HGF treatment.
|
22890162 |
2012 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis.
|
20653770 |
2010 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts.
|
18323784 |
2008 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
The single nucleotide polymorphisms of matrix metalloproteinase-1 in patients with systemic sclerosis.
|
18506448 |
2008 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, the coordinated down-regulation of collagen and TIMP-1 and up-regulation of MMP-1 renders proteasome blockade an attractive strategy for treating conditions as SSc, characterized by excessive fibrosis.
|
16410344 |
2006 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both ATX-S10(Na)-PDT and ALA-PDT increased the expression of MMP-1 and MMP-3 in protein and mRNA levels in both normal and scleroderma fibroblasts with more potent effect by ATX-S10(N)-PDT.
|
16977444 |
2006 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts.
|
15675950 |
2005 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the addition of anti-alpha(v)beta3) Ab reversed the expression of type I procollagen protein and MMP-1 protein, the promoter activity of human alpha2(I) collagen gene, and the myofibroblastic phenotype in scleroderma fibroblasts.
|
16301681 |
2005 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data show that 5-aminolevulinic acid and light induce matrix metalloproteinase 1 and matrix metalloproteinase 3 expression in normal and scleroderma fibroblasts in a singlet oxygen-dependent way while reducing collagen type I mRNA expression.
|
12542540 |
2003 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The expression of matrix metalloproteinase-1 mRNA induced by ultraviolet A1 (340-400 nm) is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis.
|
12692352 |
2003 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings indicated that the relatively stronger increase in MMP-1 expression in SSc fibroblasts was due to the lower antioxidant capacity.
|
12692352 |
2003 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, MMP-1 promoter genotypes did not significantly correlate with any of the major clinical manifestations of SSc.
|
11528521 |
2001 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cultured fibroblasts from patients with systemic sclerosis (SSc) and normal individuals were examined for gene expression of types I and III collagen, decorin, matrix metalloproteinases (MMP) MMP-1, MMP-2, and MMP-3, tissue inhibitors of metalloproteinases (TIMP) TIMP-1 and TIMP-2, urokinase- and tissue-type plasminogen activators (u-PA and t-PA).
|
9373715 |
1997 |